Oxford Biomedica Plc(OXB)

Description: Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.

---

Keywords: Medicine Cancer Disease Pipe Parkinson's Disease Cell Therapy Virotherapy Platform Technology Wet Age Related Macular Degeneration Gene Delivery Xf Cell Therapy Products Molecular Genetics Bioprocessing Oxb Process Development Services Viral Vector Cancer Disease Cell Therapy Product Lentivirus

---

Home Page: www.oxb.com

OXB Technical Analysis

Windrush Court
Oxford, OX4 6LT
United Kingdom
Phone: 44 1865 783 000

---

Officers

Exchange: LSE

Country: UK

Currency: Pence sterling (p)